<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033276</url>
  </required_header>
  <id_info>
    <org_study_id>20180138795</org_study_id>
    <nct_id>NCT04033276</nct_id>
  </id_info>
  <brief_title>IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies</brief_title>
  <official_title>A Randomized, Open, Controlled Trial of High Dose IVIG/Rituximab Versus Rituximab in Kidney Transplant Patients With de Novo Donor-specific Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare two strategies of de novo donor specific
      antibodies (DSA) and antibody-mediated rejection (AMR) prevention in renal transplant
      recipients: high dose intravenous immunoglobulin (IVIG)/rituximab regimens versus rituximab
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although recent advances in immunosuppressive regimens after kidney transplantation (KT) have
      reduced the incidence and consequences of T-cell-mediated rejection (TCMR) and have improved
      short-term outcomes, long-term allograft loss attributable to AMR is still responsible for
      substantial medical and socioeconomic burdens in kidney transplant recipients. Numerous
      studies have shown that de novo DSA after KT are associated with AMR, which leads to
      allograft loss. IVIG is a medication that has emerged as a useful tool in modulating
      immunity, treatment of AMR and in desensitization protocol. Treatment with rituximab or
      combination of IVIG/rituximab has sought to further diminish antibody production (de novo
      DSA) in the treatment of AMR. Several studies have been reported, but in the absence of
      control groups or standardization of treatment, their efficacy is difficult to assess.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in delta DSA MFI sum</measure>
    <time_frame>baseline and 3 months post-treatment, 1 year post-treatment</time_frame>
    <description>change of pre- and post-treatment DSA MFI sum, monitoring DSA during follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate(eGFR) by CKD-EPI equation</measure>
    <time_frame>baseline and 3 months post-treatment, 1 year post-treatment</time_frame>
    <description>change of pre- and post-treatment eGFR by CKD-EPI equation, monitoring eGFR during follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of antibody-mediated rejection (AMR)</measure>
    <time_frame>up to 1 year post-treatment</time_frame>
    <description>To identify the development of AMR after treatment during follow-up period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inj Rituximab 375mg/m2 IV given on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of high-dose IVIG and Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>IV rituximab</description>
    <arm_group_label>Combination of high-dose IVIG and Rituximab</arm_group_label>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immune globulin</intervention_name>
    <description>iv intravenous immune globulin</description>
    <arm_group_label>Combination of high-dose IVIG and Rituximab</arm_group_label>
    <other_name>IVIG-SN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients have de novo production of DR or DQ DSA after renal transplantation Inclusion
        criteria requires all of the following

          1. age ≥ 19 years

          2. Renal transplants with eGFR ≥ 20 ml/min (by CKD-EPI equation) and change in the eGFR ≤
             20 within 3 months

          3. No history of biopsy proven acute T cell mediated rejection or antibody-mediated
             rejection within 3 months

          4. peak MFI of de novo DSA (DR or DQ) ≥ 1000

          5. A patient who agree to write a written consent form

        Exclusion Criteria:

          1. age ≤ 18 years

          2. multi-organ transplantation

          3. Patients with no history of tacrolimus as immunosuppressants

          4. history of allergic or anaphylactic reaction to rituximab

          5. human immunodeficiency virus infection

          6. active infection

          7. pregnancy or lactation

          8. history of drug abuse or alcohol abuse within 6 months

          9. history of malignancy within 5 years

         10. history of treatment for psychiatric problems

         11. hematologic or biochemical abnormalities (Hb &lt; 7g/dL, Platelet &lt; 1x105/mm3, AST/ALT &gt;
             80IU)

         12. A patient who do not want to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaeseok Yang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaeseok Yang, M.D., Ph.D.</last_name>
    <phone>82-2-2072-4128</phone>
    <email>jcyjs@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tai Yeon Koo, M.D., Ph.D.</last_name>
    <phone>82-2-2072-4014</phone>
    <email>marvin77@empas.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaeseok Yang, M.D., Ph.D.</last_name>
      <phone>82-2-2072-4128</phone>
      <email>jcyjs@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Tai Yeon Koo, M.D., Ph.D.</last_name>
      <phone>82-2-2072-4014</phone>
      <email>marvin77@empas.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu Ha Huh, M.D., Ph.D..</last_name>
      <email>khhuh@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

